Sputnik V receives DCGI approval, makes it 3rd corona vaccine for India

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

India on Monday approved Russian jab Sputnik V as the third Covid-19 vaccine for restricted use in the country. The vaccine was developed by the Gamaleya Research Institute (GRI) of Russia, and funded and promoted outside by the Russian Direct Investment Fund (RDIF).

In India, the RDIF's partner is Dr Reddy's Laboratories, which conducted clinical trials - mandatory for approval - India. Sputnik-V became the first vaccine to be announced last year for protection against Covid-19.

It works on complex biotechnology in which another virus is employed to carry the DNA code required for triggering an immune response in human cells. Sputnik V's approval has come at a time when the country is reeling under a shortage of existing two vaccines - Covishield and Covaxin.

India has a combined production capacity of around 6.40 crore doses a month of the two approved vaccines in a month. Covishield-maker Serum Institute of India (SII) is shouldering the major burden as the other vaccine-manufacturer, the Bharat Biotech has a limited capacity of 40 lakh doses a month.

Several states have flagged in recent days that both Covishield and Covaxin are in short supply. Reports of vaccination centres from Varanasi in Uttar Pradesh to Mumbai in Maharashtra appeared last week.

Vaccine shortage became an issue of a political fight between the Centre and the Opposition-ruled governments in the backdrop of the second wave of Covid-19 pandemic wreaking havoc in at least 10 states. Maharashtra, Delhi, Chhattisgarh, Punjab, Madhya Pradesh, Kerala, and Uttar Pradesh are among severely impacted states.

The supply of the third vaccine is bound to strengthen the Covid-19 vaccination drive across the country.

Sputnik V, named after the first Soviet space satellite, showed a better efficacy during trials compared to the vaccines already in use in India. Both Covishield and Covaxin showed the efficacy of around 81 per cent in the trials, Sputnik V returned with 91-92 per cent efficacy.

On the production front, the Russian Direct Investment Fund (RDIF) has tied up with Indian pharmaceutical firms such as Dr Reddy's Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech for the manufacturing the vaccine doses.

These firms jointly have an annual production capacity of 850 million doses for Sputnik V. This makes Sputnik V's approval a big shot in the arm in the fight against the Covid-19 pandemic.

It is expected that the doses of the Sputnik V vaccine will be available at vaccination centres by June this year. There are at least four more vaccines that are expected to get approval from the Drug Controller General of India (DCGI) by the year-end.







Tags : #SputnikV #RussianVaccineforCorona #EfficacyofRussianVaccine #DrReddysLab #SerumInstituteofIndia #BharatBiotech #DCGI #LatestNewsonCOVIDVaccine13thApr

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scientists in Moscow Develop Fetal Phantom for Obstetric UltrasoundNovember 19, 2024
International Men’s Day: A Celebration of Strength, Vulnerability, and ChangeNovember 19, 2024
The Bloody Truth: Why Menstruation Is Still a Taboo in Indian SchoolsNovember 19, 2024
Toxic Air, Fragile Hearts: The Hidden Cost of Pollution on Heart Failure PatientsNovember 19, 2024
Government of Telangana Hosts the AI in Healthcare Summit – Road to BioAsia 2025November 18, 2024
In yet another groundbreaking medical milestone, Sarvodaya Hospital successfully performs India’s youngest cochlear implant on a 5- month old babyNovember 18, 2024
Sightsavers India in collaboration with AbbVie Therapeutics India Private Limited Hosted the 4th State-Level Consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’November 16, 2024
Is Your Saree Hurting You? How Tight Waist Petticoats Could Trigger Skin CancerNovember 16, 2024
10 New-born Lives Lost: The Jhansi Hospital Fire That Shook India’s ConscienceNovember 16, 2024
Streax introduces revolutionary Shampoo Hair Colour in South India at accessible price point.November 15, 2024
The Silent Killer in Your Genes: Can Splicing Errors Unlock New Cancer Cures?November 15, 2024
Stress on a Schedule: What Your Gut Bacteria Know That You Don’tNovember 15, 2024
A Preventable Catastrophe: Why Are Children Still Dying from Measles?November 15, 2024
The University of Tasmania invites applications for Master of Marine and Antarctic ScienceNovember 14, 2024
ICMR’s Bold Bet: Can India’s Scientists Deliver World-First Health Breakthroughs?November 14, 2024
The Dark Reality Behind India’s Ayushman Bharat: Profits Before Patients?November 14, 2024
Not a Fan of Exercise? Here’s How Few Steps You Actually Need for Better HealthNovember 14, 2024
Shiprocket launches AI Powered Shiprocket Copilot to empower a Self-Reliant Digital Future for over 1,00,000+ Indian MSMEsNovember 13, 2024
AIIMS Darbhanga and More: Can PM Modi’s 12,000 Crore Investment Turn Bihar into India’s Next Growth Engine?November 13, 2024
Self-Made Survivor: How a Virologist Battled Breast Cancer with Her Own Lab-Grown VirusesNovember 13, 2024